HeartSciences ROE 2022-2024 | HSCS
Current and historical return on equity (ROE) values for HeartSciences (HSCS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| HeartSciences ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-07-31 | $-0.01B | $0.01B | -160.00% |
| 2024-04-30 | $-0.01B | $0.01B | -215.38% |
| 2024-01-31 | $-0.01B | $0.01B | -466.67% |
| 2023-10-31 | $-0.01B | $-0.00B | 800.00% |
| 2023-07-31 | $-0.01B | $-0.00B | inf% |
| 2023-04-30 | $-0.01B | $0.00B | -700.00% |
| 2023-01-31 | $-0.01B | $0.00B | 1400.00% |
| 2022-10-31 | $-0.01B | $0.00B | 1400.00% |
| 2022-07-31 | $-0.01B | $0.00B | 800.00% |
| 2022-04-30 | $-0.01B | $-0.01B | 333.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.003B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $11.978B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $6.055B | 188.82 |
| Hims & Hers Health (HIMS) | United States | $5.988B | 154.89 |
| Axonics (AXNX) | United States | $3.602B | 1762.00 |
| IRhythm Technologies (IRTC) | United States | $2.783B | 0.00 |
| Privia Health (PRVA) | United States | $2.736B | 228.00 |
| Enovis (ENOV) | United States | $2.646B | 17.94 |
| Omnicell (OMCL) | United States | $2.263B | 74.03 |
| Azenta (AZTA) | United States | $2.242B | 127.33 |
| 10x Genomics (TXG) | United States | $1.925B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.657B | 0.00 |
| Schrodinger (SDGR) | United States | $1.422B | 0.00 |
| Phreesia (PHR) | United States | $1.252B | 0.00 |
| Standard BioTools (LAB) | United States | $0.830B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.613B | 0.00 |
| Talkspace (TALK) | United States | $0.586B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.582B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.508B | 88.00 |
| Health Catalyst (HCAT) | United States | $0.506B | 0.00 |
| Pulmonx (LUNG) | United States | $0.298B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.248B | 0.00 |
| TruBridge (TBRG) | United States | $0.214B | 62.22 |
| P3 Health Partners (PIII) | United States | $0.142B | 0.00 |
| American Well (AMWL) | United States | $0.139B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.106B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.064B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.050B | 0.00 |
| Outset Medical (OM) | United States | $0.045B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.042B | 0.00 |
| CareCloud (CCLD) | United States | $0.042B | 0.00 |
| Movano (MOVE) | United States | $0.028B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.018B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |